Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities researchers at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research note issued to investors on Monday, May 19th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings of ($0.23) per share for the quarter, down from their previous forecast of ($0.17). The consensus estimate for Aldeyra Therapeutics' current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics' Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.85) EPS, FY2026 earnings at $1.90 EPS, FY2027 earnings at ($0.35) EPS and FY2028 earnings at $0.85 EPS.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.08.

Several other research firms also recently commented on ALDX. StockNews.com raised shares of Aldeyra Therapeutics to a "sell" rating in a research note on Wednesday. BTIG Research decreased their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Monday.

Aldeyra Therapeutics Stock Performance

Shares of Aldeyra Therapeutics stock opened at $2.25 on Thursday. Aldeyra Therapeutics has a 52 week low of $1.14 and a 52 week high of $7.20. The company has a market capitalization of $134.77 million, a PE ratio of -2.32 and a beta of 0.92. The stock's fifty day moving average is $3.29 and its two-hundred day moving average is $4.67. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALDX. Hsbc Holdings PLC acquired a new stake in Aldeyra Therapeutics in the fourth quarter worth about $52,000. Capital Advisors Wealth Management LLC purchased a new position in shares of Aldeyra Therapeutics in the 1st quarter valued at approximately $62,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Aldeyra Therapeutics in the 1st quarter worth approximately $63,000. Balyasny Asset Management L.P. acquired a new stake in Aldeyra Therapeutics in the 4th quarter worth approximately $56,000. Finally, Catalyst Funds Management Pty Ltd grew its position in Aldeyra Therapeutics by 2,083.3% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 12,500 shares during the last quarter. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company's stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares of the company's stock, valued at approximately $8,343,708.42. This represents a 36.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 9.60% of the company's stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.